Adnan Kastrati, MD
Deutsches Herzzentrum Muenchen
Emerging Leaders
not ranked
Current Leaders
not ranked
All-Time Leaders
#2089 pts
Scored by the scientific impact (publications, citations, press) of the trials they lead, weighted by role. First trial 2001. 24 trials as lead/chair. How it works →
Trials led — by scientific impact
Prospective, Randomized Trial of Rapamycin Plus Estradiol-Eluting Stents Versus Rapamycin-Eluting Stents For The Reduction of Coronary Restenosis (ISAR-PEACE)
Phase 4CompletedDeutsches Herzzentrum Muenchen
8
impact
Prospective, Randomized Trial of 3 Rapamycin-Eluting Stents With Different Polymer Coating Strategies For The Reduction of Coronary Restenosis (ISAR-TEST-3)
Phase 4CompletedDeutsches Herzzentrum Muenchen
8
impact
Randomized Comparison of 3 Limus Agent-Eluting Stents for the Reduction of Coronary Restenosis
Phase 4CompletedDeutsches Herzzentrum Muenchen
7
impact
Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)
Phase 4CompletedDeutsches Herzzentrum Muenchen
6
impact
Prospective, Randomized Trial of the Sirolimus-Eluting Stent and Paclitaxel-Eluting Stent for the Treatment of Unprotected Left Main Coronary Artery Disease(ISAR-LEFT-MAIN)
Phase 4CompletedDeutsches Herzzentrum Muenchen
6
impact
Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of the Glycoprotein IIb/IIIa Inhibition With Abciximab in Patients With ACS Undergoing Coronary Stenting After Pretreatment With a High Loading Dose of Clopidogrel (ISAR-REACT-2)
Phase 4CompletedDeutsches Herzzentrum Muenchen
6
impact
Value of Abciximab in Patients With AMI Undergoing PCI After High Dose Clopidogrel Pretreatment (BRAVE 3)
Phase 4CompletedDeutsches Herzzentrum Muenchen
6
impact
Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3
Phase 4CompletedDeutsches Herzzentrum Muenchen
5
impact
A Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Prevention of Restenosis (ISAR-TEST-1)
Phase 4CompletedDeutsches Herzzentrum Muenchen
5
impact
Randomized Trial of Paclitaxel-Eluting Stent and Sirolimus-Eluting Stent for Restenosis Reduction in Small Coronary Vessels (ISAR-SMART-3)
Phase 4CompletedDeutsches Herzzentrum Muenchen
5
impact
Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting STents (ISAR-TEST 4): Prospective, Randomized Trial of 3-limus Agent-eluting Stents With Different Polymer Coatings
Phase 4CompletedDeutsches Herzzentrum Muenchen
4
impact
Prospective, Randomized Trial of Rapamycin- and Zotarolimus-eluting Stents for the Reduction of Coronary Restenosis
Phase 4CompletedDeutsches Herzzentrum MuenchenStudy Chair
4
impact
A Prospective, Placebo-Controlled, Double-Blind, Randomized Study Evaluating the Efficacy of Non-Polymer-Based Coating With Two Different Rapamycin-Dosages for the Prevention of Restenosis After Percutaneous Coronary Interventions
Phase 4TerminatedTranslumina GmbH
4
impact
Prospective Randomized Trial of Everolimus- and Zotarolimus-eluting Stents for Treatment of Unprotected Left Main Coronary Artery Disease: ISAR-LEFT-MAIN-2
Phase 4CompletedDeutsches Herzzentrum MuenchenStudy Chair
3
impact
Randomized Trial of Paclitaxel- vs Sirolimus-eluting Stents for Treatment of Coronary Restenosis in Sirolimus-eluting Stents
Phase 4CompletedDeutsches Herzzentrum Muenchen
3
impact
Prospective, Randomized Trial of Drug-eluting Stents vs. Bare Metal Stents for the Reduction of Restenosis in Bypass Grafts.
Phase 4CompletedDeutsches Herzzentrum MuenchenStudy Chair
3
impact
A Randomized Clinical Trial of Stem Cell Mobilization by Granulocyte-Colony-Stimulating Factor in Patients With Acute Myocardial Infarction. Regenerate Vital Myocardium by Vigorous Activation of Bone Marrow Stem Cells (REVIVAL-2) Trial
Phase 4CompletedDeutsches Herzzentrum Muenchen
2
impact
Randomized Trial of Prasugrel Plus Bivalirudin vs. Clopidogrel Plus Heparin in Patients With Acute STEMI
Phase 4UnknownDeutsches Herzzentrum MuenchenStudy Chair
2
impact
A Randomized, Double-Blind, Placebo-Controlled Trial Investigating the Impact of Oral Sirolimus on Restenosis Prevention in Patients With In-Stent Restenosis.
Phase 4CompletedDeutsches Herzzentrum Muenchen
2
impact
An International, Multicenter, Randomized Trial Assessing the Value of Mechanical Reperfusion in Patients With Acute Myocardial Infarction Presenting > 12 Hours From Onset of Symptoms
Phase 4CompletedDeutsches Herzzentrum Muenchen
2
impact
Randomized, Double-Blind, Placebo-controlled Trial of 6 vs. 12 Months Clopidogrel Therapy After Implantation of a Drug-Eluting Stent
Phase 4UnknownDeutsches Herzzentrum Muenchen
1
impact
Randomized Trial of Paclitaxel Eluting Balloon or Conventional Balloon for Treatment of In-Stent Restenosis of the Superficial Femoral Artery in Patients With Symptomatic Peripheral Artery Disease (ISAR-PEBIS)
Phase 4UnknownDeutsches Herzzentrum MuenchenStudy Chair
1
impact
Prospective, Randomized, Double-Blind Trial of Abrupt and Tapered Interruption of Long-term Clopidogrel Therapy After Implantation of a Drug-Eluting Stent
Phase 4TerminatedDeutsches Herzzentrum MuenchenStudy Chair
1
impact